Replies

Pharma Giant Paid ‘Elite’ Obesity Specialists $25.8 Million To Promote Weight Loss Drugs

https://creativedestructionmedia.com/news/business/2023/12/11/pharma-giant-paid-elite-obesity-specialists-25-8-million-to-promote-weight-loss-drugs/

Excerpt:

An “elite” and influential group of obesity specialists over the last decade pocketed at least $25.8 million in payments from Novo Nordisk, maker of weight loss drugs Wegovy and Saxenda, in exchange for promoting the drugs in their lectures, treatment guidelines, clinics and medical societies, according to an investigation by Reuters.

“Those payments are part of a campaign to convince U.S. doctors to make Wegovy one of the most widely prescribed drugs in history — and to persuade skeptical insurers to pay for it,” according to the report.

Wegovy and Saxenda have rapidly transformed the treatment of obesity in the U.S., with a boom in prescriptions so big in 2023 that JP Morgan doubled its 10-year sales projection, predicting sales of $71 million for the drugs by 2032.

Despite the drugs’ serious side effects — including major gastrointestinal issues, self-harm behaviors and cancers — the Association of American Pediatrics recommends the drugs in its new clinical guidelines, the American Medical Association urges insurance carriers to cover the drugs, and the mainstream and medical press heavily promote them.

n “elite” and influential group of obesity specialists over the last decade pocketed at least $25.8 million in payments from Novo Nordisk, maker of weight loss drugs Wegovy and Saxenda, in exchange for promoting the drugs in their lectures, treatment guidelines, clinics and medical societies, according to an investigation by Reuters.

.....Dr. Arthur Kellermann, a health administrator and former dean of the Uniformed Services University of Health Sciences, the U.S. military’s medical school, told Reuters the investigation sheds light on a long-standing problem in the drug industry.

He called the payments “morally and ethically way over the line,” adding:

“The pharmaceutical industry still sees value in paying medical thought leaders to promote their products, and too many of them are happy to sign up for a six- or seven-figure check …

”As sales grow, Medicare and the insurance industry come under intense pressure to pay for these hugely expensive drugs … The end result is that everybody’s healthcare costs go up.”

Another recent report by investigative journalist Lee Fang similarly found a wide network of celebrities, physicians, patient advocacy groups, public health experts, academics, and community leaders have appeared in dozens of media outlets to tout the drugs without disclosing their financial ties to Novo Nordisk.

Which doctors take money from Novo Nordisk?

For example, Novo paid Lee Kaplan, M.D., Ph.D., chief of obesity medicine at Dartmouth’s medical school, former head of Obesity, Metabolism and Nutrition Institute at Massachusetts General Hospital, and associate professor of medicine at Harvard, $1.4 million for consulting work and travel related to the two drugs between 2013 and 2022.

.....Another physician, Dr. Donna Ryan, former president of The Obesity Society and member of The Diplomate at the American Board of Obesity Medicine, has taken more than $1 million from Novo over the last decade, including $600,691 related to Wegovy and Saxenda.

Ryan was instrumental in persuading the U.S. Office of Personnel Management to cover Wegovy and similar drugs for millions of federal workers, an agency official told Reuters.

.....STOP medical director Dr. Scott Kahan, who will assist in writing The Obesity Society’s new “standards-of-care” guidelines that primary-care doctors commonly use as a quick-reference guide, has accepted more than $300,000 from Novo.

Dr. Jamy Ard, of Wake Forest University, the incoming president of The Obesity Society who will oversee the guideline writing, has taken over $200,000 from Novo.

She, Dr. Ryan, and obesity specialist Dr. Ken Fujioka, director of the Scripps Clinic Nutrition and Metabolic Research Center in San Diego, have taken 130 Novo-paid trips over the past decade, traveling to make speeches and do consulting.

.....The 2020 U.S. approval of Novo Nordisk’s Saxenda, a once-daily injection for weight loss, opened a new era of pharmaceutical-based weight management, The Defender reported.

This was followed, in June 2021, by the licensing of Wegovy, and less than a year later of Ozempic, which is indicated for Type 2 diabetes, but contains the same active ingredient, semaglutide, as Wegovy, and is prescribed off-label for weight loss.

Semaglutide drugs are taken as a once-weekly injection, which is considered a benefit compared to a once-daily jab. Liraglutide is a daily shot. Semaglutide is also available as a once-daily pill under the brand name Rybelsus, another Novo drug.

These drugs mimic the GLP-1 hormone, which assists patients in losing weight by regulating their appetite.

In November 2023, the FDA approved Eli Lilly’s Zepbound, another injectable diabetes drug, for weight loss. The active ingredient in Zepbound, tirzepatide, sets this drug apart from Wegovy and Ozempic but it works similarly through a weekly injection.

Tirzepatide is sold by Eli Lilly as a diabetes drug under the trade name Mounjaro.

.....The surging popularity of the medication led to shortages and made Novo Nordisk one of the most valuable global pharmaceutical companies, behind Johnson & Johnson and Eli Lilly.

The shortages raised concerns because the drugs are not made for short-term use. Studies show that when people stop taking them, they regain much of the weight they lost, or potentially gain even more weight. Most people who start taking the drugs and want the effects to last will have to stay on them long-term.

But recent pharmacy claims data shows that most people who start taking Wegovy stop taking it within a year, some because of side effects and some because of the high cost of the drugs.

In addition to suicidal ideation and thoughts of self-harm, pancreatic cancer and gastrointestinal disorders, other adverse effects linked to semaglutide are also becoming apparent. A study using data from EudraVigilance, also found metabolic, nutritional, eye, renal, urinary and cardiac disorders were also reported.

The drugs also carry serious and under-discussed risks for pregnant women.

Despite the high drug cost and the associated risks, there is an ongoing debate about whether insurance companies and Medicare should cover the cost of weight loss drugs, which would increase profits exponentially.

Reuters reported that Wegovy’s U.S. prescribing label recommends the drug for anyone with a body mass index (BMI) of 30 or higher, the threshold for obesity and for people with a 27 BMI who also have a weight-related medical condition.

That would cover about 46% of American adults — about 120 million people, according to the report.

A study published in March in the NEJM estimated that if Medicare were compelled to cover Wegovy, with an estimated 23% discount, it would cost $27 billion to treat just 10% of patients with obesity enrolled in Medicare. That would equal nearly a fifth of the yearly spending for Medicare’s program covering prescription drugs.
********

Once again our fast food nation seeking a quick fix to a self induced problem, obesity. This also crowds out the Type II diabetics that are the intended users of the medicine. Also in their rush to fix their obesity they ignore the potential side effects, which are severe for these drugs.

Side note: Had a family friend who is classified as obese have her GP prescibe Wegovy. Her doctor did but stated it was for weight loss, she is not a diabetic. Medicare denied the script. If she wanted it would have to be out of pocket to the tune of $1,098.00 every 30 days. Needless to she did not fill the script.